<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00122226</url>
  </required_header>
  <id_info>
    <org_study_id>protocol 02-72</org_study_id>
    <nct_id>NCT00122226</nct_id>
  </id_info>
  <brief_title>MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)</brief_title>
  <official_title>MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <brief_summary>
    <textblock>
      This is a randomized prospective study into metabolic adverse events during different types
      of initial antiretroviral therapy in HIV-1-infected men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized prospective study into metabolic adverse events during initial
      antiretroviral therapy in HIV-1-infected men. The following regimens are compared:
      lopinavir-ritonavir + Combivir and lopinavir-ritonavir + nevirapine (nucleoside reverse
      transcriptase inhibitor [NRTI]-sparing). Prior to the start of therapy and 3, 12, 24, and 36
      months thereafter the distribution of body fat and bone density (bioelectrical impedance
      analysis [BIA], computed tomography [CT] and dual energy x-ray absorptiometry [DEXA]), lipid
      spectrum, mitochondrial DNA (peripheral blood mononuclear cells [PBMCs] and adipose tissue
      biopsies) and vascular measurements are performed. In addition, insulin sensitivity is
      measured in a subgroup of sixteen individuals by using a hyperinsulinemic euglycemic clamp
      and performing microvascular measurements. The aim of the study is to obtain prospective
      insight into the occurrence of various aspects of metabolic adverse events on the one hand
      and to compare an NRTI-containing therapy with an NRTI-sparing therapy on the other hand. The
      hypothesis is that in the NRTI-sparing arm, less metabolic and vascular changes are observed
      than in the NRTI containing regimen.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2003</start_date>
  <completion_date>July 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin resistance (3, 12, 24, 36 months)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>microvascular function (3, 12, 24, 36 months)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>lipid profile (3, 12, 24, 36 months)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>body composition (3, 12, 24, 36 months)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>macrovascular function (12, 24, 36 months)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>mitochondrial DNA in PBMC and fatty tissue (12, 24, 36 months)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gene expression, markers of mitochondrial toxicity, inflammation, apoptosis, fat cell differentiation in fatty tissue (12, 24, 36 months)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone mineral density (12, 24, 36 months)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>natural killer cells (3, 12, 24 months)</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>HIV Infections</condition>
  <condition>HIV-Associated Lipodystrophy Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir + zidovudine + lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir + nevirapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Age between 18 and 70 years.

          -  No prior use of antiretroviral therapy

          -  Indication for antiretroviral treatment according to common standards

        Exclusion Criteria:

          -  Female sex

          -  Body mass index (kg/m2) &gt; 35.

          -  Known history of diabetes mellitus or hyperlipidemia

          -  Use of coenzyme A reductase inhibitor or fibric acid derivative in the last 6 weeks
             before inclusion

          -  Use of the following medication: systemic corticosteroids, thiazide diuretics,
             calcium-entry blockers, angiotensin-converting inhibitors, nitrates

          -  Use of nandrolone or testosterone

          -  Any disorder or condition which can be expected to lead to lessened compliance with
             the study protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. A. Danner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Free University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. Reiss, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center, National AIDS Therapy Evaluation Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Jan van Goyen</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis, location Oosterpark</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis, location Prinsengracht</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slotervaart ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VUMC Free University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Leyenburg</name>
      <address>
        <city>den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis, location Elisabeth</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Universitair Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2005</study_first_submitted>
  <study_first_submitted_qc>July 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <last_update_submitted>April 24, 2006</last_update_submitted>
  <last_update_submitted_qc>April 24, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2006</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>HIV-associated lipodystrophy syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

